BEAM-304
Gene therapy / editing
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
No matching registered study is currently available for this indication; source coverage requires resolution.
No registered study of this drug names Phenylketonuria in its conditions or title.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
This drug's own stage for Phenylketonuria: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| BEAM-304: this drug | Stage not on record | Gene therapy / editing | PAH gene (phenylalanine hydroxylase) | not yet graded | No reviewed efficacy summary in this indication | |
| Pegvaliase (PALYNZIQ) | Approved | Protein / enzyme therapeutic | Phenylalanine ammonia lyase (enzyme substitution) | Weak signal | Featured results are safety only in this race | |
| Sapropterin Dihydrochloride (Kuvan) | Approved | Small molecule | Phenylalanine hydroxylase (PAH) | Reliable signal | NCT00104247: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36) NCT00272792: Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009). | |
| Sepiapterin | Approved | Small molecule | Phenylalanine hydroxylase (PAH) | Reliable signal | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.